Home 2019
Archives
ASCO: Survival Up With Ribociclib in Advanced Breast Cancer
OS longer for premenopausal patients receiving ribociclib in addition to endocrine therapy
ASCO: Combo Regimen Effective in CLL With Coexisting Conditions
Progression-free survival longer with venetoclax-obinutuzumab versus chlorambucil-obinutuzumab
ASCO: Olaparib Beats Placebo for BRCA-Related Pancreatic Cancer
Progression-free survival significantly improved with olaparib versus placebo for metastatic disease
ASCO: Low-Dose Chemo Benefits Advanced Gastroesophageal Cancer
Elderly, frail receiving 60 percent of oxaliplatin/capecitabine dose have noninferior PFS, less toxicity
ASCO: Pembrolizumab Noninferior to Chemo in Advanced Gastric Cancer
For patients with PD-L1 combined positive score of ≥10, pembrolizumab prolongs overall survival
LDL Decreased With LDL-Apheresis in ACS Patients
Significant reduction seen in mean LDL among patients with acute coronary syndrome treated with PCI
High-Deductible Health Plans May Be Harmful for Patients With COPD
Individuals with HDHP more likely to report forgoing care due to costs, cost-related nonadherence
Decrease in PM2.5-Related U.S. Mortality From 2010 to 2017
During the same period, ozone-related mortality remained mainly unchanged
Women With COPD Have Worse QoL, Increased Symptom Burden
Women are more likely to be symptomatic, have greater odds of frequent, severe acute exacerbations
Closed ICU Model May Reduce Hospital-Acquired Infections
Decline seen in CLABSI, CAUTI, VAP rates; no change in C. diff infection, MRSA blood infection rates
